Dr. Moore’s extensive tenure at Mayo Clinic, spanning over three decades, is characterized by his pioneering work in head and neck surgery, particularly his mastery of minimally invasive techniques. His expertise in transoral robotic surgery (TORS) represents a paradigm shift in the treatment of head and neck cancers, reducing patient recovery times and enhancing surgical precision. This cutting-edge approach employs robotic systems that allow surgeons to navigate complex anatomical structures with enhanced visualization and dexterity, leading to improved functional outcomes and diminished postoperative morbidity.

Beyond surgical innovation, Dr. Moore’s multidisciplinary appointments across divisions such as Oral and Maxillofacial Surgery, Neurosurgery, and Pediatrics underscore his holistic approach to otolaryngologic care. These collaborative roles foster integrated treatment regimens that address the multifaceted nature of ENT disorders, ensuring patients receive comprehensive therapeutic interventions that span anatomical and specialty boundaries.

Educated at Jefferson Medical College, Dr. Moore honed his skills during a rigorous residency in otolaryngology-head and neck surgery at Mayo Clinic from 1992 to 1997, followed by a specialized fellowship in endoscopic skull base surgery in Graz, Austria. His additional military service as a United States Air Force major brought unique perspectives on leadership and discipline, further enriching his clinical acumen. This blend of academic rigor and practical experience has fueled his evolution into a mentor and educator, recognized repeatedly with the Mayo Fellows Teacher of the Year Award for his dedication to cultivating future generations of surgeons.

The Mayo Clinic Board of Trustees, comprised of a dynamic mix of public representatives and seasoned clinicians and administrators, steers the institution’s mission across its diverse campuses in Arizona, Florida, and Minnesota, as well as the extended Mayo Clinic Health System. Dr. Moore’s involvement promises to strengthen governance with insights drawn from his frontline clinical and administrative roles, advancing strategies that respond adeptly to emerging medical challenges and technological frontiers.

Healthcare today is increasingly defined by the convergence of artificial intelligence, precision medicine, and minimally invasive techniques. Within this context, Dr. Moore’s leadership at Mayo Clinic International positions him uniquely to champion initiatives fostering global collaboration and knowledge exchange, crucial for addressing complex ENT cases worldwide. His advocacy for coordinated, patient-centered care aligns seamlessly with Mayo Clinic’s ethos, elevating standards while maintaining compassion and accessibility.

Notably, the board’s recent elections reaffirm its stability and visionary character, with notable figures like Dr. Matthew Callstrom and Dr. Abimbola Famuyide continuing their influential tenures. Callstrom’s expertise in radiology and artificial intelligence strategy complements Moore’s clinical focus, illustrating Mayo Clinic’s holistic emphasis on integrating technological innovation with patient care. Similarly, Famuyide’s specialization in obstetrics and gynecology research enhances the board’s multidisciplinary competency.

Honoring legacy and innovation, the board also acknowledged Eric Schmidt, former CEO of Google and current CEO of Relativity Space, as an emeritus trustee. Schmidt’s leadership in technology and aerospace exemplifies the board’s commitment to intersecting healthcare with cutting-edge technological developments, a philosophy mirrored in Dr. Moore’s robotic surgery contributions.

Dr. Moore’s strategic vision is timely. The future of otolaryngology depends not only on surgical precision but also on harnessing data analytics, machine learning, and global health partnerships to anticipate and respond to complex disease patterns. His appointment suggests that Mayo Clinic will remain at the forefront of this integration, driving both clinical excellence and operational agility.

By navigating the challenges of increasingly intricate head and neck pathologies through innovation and collaboration, Dr. Moore exemplifies Mayo Clinic’s mission to innovate relentlessly while delivering compassionate care. His election to the board ensures that Mayo Clinic’s governance reflects frontline expertise, fostering breakthroughs that will benefit patients locally and globally for decades to come.

As Mayo Clinic continues expanding its reach and influence, Dr. Moore’s proven track record in education, research, and clinical leadership provides a cornerstone for the institution’s next chapter. His role affirms a future where sophisticated surgical techniques, informed by robust academic inquiry and cross-disciplinary cooperation, transform the lives of patients facing some of the most challenging medical conditions.

In an evolving landscape where technology and humanity converge, Eric J. Moore’s elevation to the Mayo Clinic Board of Trustees heralds a new era defined by visionary leadership, surgical innovation, and a steadfast commitment to worldwide health advancement.

Subject of Research: Innovations in head and neck surgery, particularly transoral robotic surgery and multidisciplinary treatment approaches for complex ENT conditions.

News Publication Date: February 20, 2025

Web References:

• Mayo Clinic Board of Trustees
• Eric Moore, M.D. Biography

Keywords: Health care, Otolaryngology, Head and neck surgery, Transoral robotic surgery, Mayo Clinic, Medical governance, Surgical innovation, Multidisciplinary care

Nerve injury during head and neck surgery is a significant clinical challenge, often resulting in debilitating functional deficits including loss of sensation, motor control, or even swallowing and speech impairments. Traditionally, surgeons have relied heavily on anatomical knowledge and intraoperative experience to identify and preserve these nerves, but this method has inherent limitations. The advent of nerve-specific fluorescent dyes represents a revolutionary technological leap, allowing surgeons to literally “see” nerves glowing in real-time under near-infrared light conditions during the procedure.

This Phase 1 clinical trial led by Lee, YJ., Orosco, R.K., Bouvet, M., and their team focused on evaluating the safety and feasibility of administering novel fluorescent agents specifically conjugated to nerve tissue markers. These agents selectively bind to peripheral nerves and emit a distinctive fluorescence, thus enhancing nerve delineation against the complex background of surrounding tissues. The trial enrolled patients undergoing various head and neck surgical interventions where nerve preservation is critical, enabling real-time assessment of the fluorescent imaging’s accuracy.

Technical nuances of the fluorescent agents used include their biocompatibility, rapid systemic clearance, and strong fluorescent signal in the near-infrared spectrum around 700–900 nm wavelengths. These properties are vital, as they avoid interference from native tissue autofluorescence and allow deeper tissue penetration of the excitation light, crucial for visualizing nerves that lie beneath multiple tissue layers. Importantly, the dyes exhibit minimal off-target binding, reducing false positives and enhancing the surgeon’s confidence in distinguishing nerve fibers from blood vessels and connective tissues.

The implications of this nerve-specific fluorescence technology extend well beyond mere visualization. By providing high-contrast images of nerve anatomy, these dyes enable more precise dissection, reducing inadvertent nerve transection or stretching. Enhanced nerve identification may result in shorter operative times and decrease the need for additional corrective surgeries. Moreover, better nerve preservation correlates strongly with improved postoperative quality of life, including preserved speech, swallowing function, and facial expressions, which are paramount to patient well-being after head and neck cancer surgeries.

Throughout the trial, patients tolerated the fluorescent agents without significant adverse effects, underscoring the biocompatibility of the compounds. Imaging sessions were seamlessly integrated into the surgical workflow, demonstrating practicality in real-world operative settings. Surgeons reported that the augmented imaging fundamentally enhanced their ability to navigate complex anatomical regions, especially around the parotid gland, skull base, and cranial nerve branches. The real-time feedback allowed dynamic adjustments during dissection, setting a new standard in surgical precision.

This approach also opens avenues for training and education, as the visualization of nerves in fluorescence mode could serve as an invaluable teaching tool for surgical trainees. It democratizes expert knowledge by making intricate nerve anatomy visually explicit rather than purely conceptual, potentially accelerating the acquisition of surgical skill and reducing the learning curve for complex head and neck procedures.

Given the Phase 1 design, the trial primarily established safety parameters and proof-of-concept efficacy rather than long-term functional outcomes. Future studies with larger cohorts and longer follow-up periods will be essential to quantify functional improvements in nerve preservation and validate the technology’s superiority over existing intraoperative nerve monitoring techniques. Researchers are optimistic about combining fluorescence imaging with other modalities like electrophysiological monitoring to create an integrated, multimodal nerve-sparing surgical platform.

The technology itself is the culmination of interdisciplinary innovation involving molecular chemistry, biomedical optics, and surgical science. The fluorescent nerve markers were painstakingly engineered to target myelin-associated glycoproteins and other nerve-specific epitopes with high affinity. The synthesis protocols ensure stability in vivo and compatibility with existing surgical imaging devices, facilitating rapid translation from bench to bedside. This cross-disciplinary collaboration epitomizes the future trajectory of personalized and precision surgery.

Importantly, the trial’s results underscore the feasibility of bringing such advanced imaging technology into routine clinical care. If further validated, this modality could become a standard adjunct in head and neck, neurosurgical, and even peripheral nerve surgeries, where detailed nerve visualization is crucial. It represents a paradigm shift from conventional ‘visible light’ surgery to fluorescence-guided interventions that enhance the surgeon’s visual acuity beyond the capabilities of the naked eye.

In a broader context, the success of nerve-specific fluorescence imaging may catalyze similar approaches targeting other critical anatomical structures such as lymphatic channels, blood vessels, and tumor margins. Multiplexed fluorescence probes with distinct spectral profiles could soon allow simultaneous visualization of multiple tissue types, further improving surgical outcomes and reducing complications.

Commercially, this technology may induce a renaissance in surgical imaging equipment development, with industry players racing to integrate nerve-specific fluorescence capabilities into existing surgical endoscopes and microscopes. Accessibility and cost-effectiveness considerations will be vital to ensure widespread adoption, especially given the global burden of head and neck cancers concentrated in resource-limited settings.

Ethically, the use of fluorescent contrast agents raises questions about safety, long-term biodistribution, and potential immunogenic responses. Thus, rigorous regulatory scrutiny and post-market surveillance will be necessary to monitor rare adverse events and ensure patient safety. The transparency of the ongoing research process, including data sharing and cross-institutional collaborations, will be key in establishing clinical confidence and public trust.

Ultimately, the Phase 1 trial by Lee and colleagues marks a milestone in surgical innovation. By transforming the invisible into the visible, nerve-specific fluorescence imaging empowers surgeons with unprecedented anatomical clarity. It signifies a hopeful future where nerve injury risks diminish and functional preservation becomes the norm rather than exception in complex head and neck surgeries.

As surgical science marches toward an era of molecular-guided precision, the optics revolution spearheaded by this study heralds new vistas of patient-centric care. The convergence of chemistry, optics, and clinical expertise epitomizes the transformative potential of interdisciplinary collaboration to solve some of medicine’s most daunting challenges.

This pioneering study lays the foundation for a new standard in surgical practice, reminding us how illuminating the unseen can fundamentally change outcomes, not only in the operating room but in the lives afterward.

Subject of Research: Intraoperative nerve-specific fluorescence visualization for enhanced nerve identification during head and neck surgery

Article Title: Intraoperative nerve-specific fluorescence visualization in head and neck surgery: a Phase 1 trial

Article References:
Lee, YJ., Orosco, R.K., Bouvet, M. et al. Intraoperative nerve-specific fluorescence visualization in head and neck surgery: a Phase 1 trial. Nat Commun 16, 6060 (2025). https://doi.org/10.1038/s41467-025-60737-x

Image Credits: AI Generated